Showing papers in "The Lancet in 2023"

TL;DR: The PANORAMIC trial as discussed by the authors showed that molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community.

TL;DR: A recent outbreak of monkeypox has been reported in the Democratic Republic of the Congo, where the incubation period ranges from 7 days to 10 days and most patients present with a systemic illness that includes fever and myalgia and a characteristic rash, with papules that evolve to vesicles, pustules, and crusts in the genital, anal, or oral regions and often involve the mucosa as discussed by the authors .

TL;DR: The DESTINY-Breast03 trial as mentioned in this paper showed an improvement in progression-free survival with trastuzumab deruxtecan versus trastusumab emtansine in patients with HER2-positive metastatic breast cancer.

TL;DR: The benefit of pharmacogenetic testing before starting drug therapy has been well documented for several single gene-drug combinations as discussed by the authors , however, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetics panel has not been rigorously assessed.

TL;DR: In this article , the authors describe the clinical characteristics and outcomes of mpox in a cohort of people with HIV and low CD4 cell counts (CD4 <350 cells per mm3).

TL;DR: In this paper , a systematic review and meta-analysis was conducted to estimate the level and characteristics of protection from past SARS-CoV-2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe disease.

TL;DR: In this article , a quantitative health impact assessment for summer (June 1-Aug 31, 2015) of the effect of urban heat islands (UHIs) on all-cause mortality for adults aged 20 years or older in 93 European cities is presented.

TL;DR: In this paper , the authors compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs.

TL;DR: In this article , the authors examined how mother and baby attributes at the individual level interact with breastfeeding determinants at other levels, how these interactions drive breastfeeding outcomes, and what policies and interventions are necessary to achieve optimal breastfeeding.

TL;DR: In this paper , the anti-obesity medications act on central appetite pathways to reduce hunger and food reward and are associated with weight losses of more than 10% of overall bodyweight in more than two-thirds of clinical trial participants.

TL;DR: Wang et al. as discussed by the authors obtained a total of 2994 complete SARS-CoV-2 genome sequences in Beijing, among which 2881 were high quality and were used for further analysis.

TL;DR: In this article , the effects on maternal and perinatal outcomes of COVID-19 during pregnancy, and evaluate vaccine effectiveness, when omicron (B.1.529) was the variant of concern.

TL;DR: In this article , the authors explain how the shift towards market fundamentalism and increasingly powerful transnational corporations has created a pathological system in which commercial actors are increasingly enabled to cause harm and externalise the costs of doing so, whereas the countervailing forces having to meet these costs (notably individuals, governments, and civil society organisations) become correspondingly impoverished and disempowered or captured by commercial interests.

TL;DR: In this paper , the authors evaluated whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin alone would improve outcomes compared with using the immunotherapy alone in advanced biliary tract cancer patients.

TL;DR: In this paper , the authors compared tenecteplase to alteplase for patients with acute ischaemic stroke. But, they did not evaluate the non-inferiority between the two drugs.

TL;DR: In this article , the authors assess novel and emerging biological treatments for major depressive disorder, evaluate their putative brain and body mechanisms, and highlight how close each might be to clinical use.

TL;DR: The BE OPTIMAL trial as discussed by the authors evaluated the efficacy and safety of bimekizumab in patients with active psoriatic arthritis who were naive to biologic disease-modifying antirheumatic drugs (DMARDs).

TL;DR: In this paper , the authors reviewed the multiple clinical dimensions of systemic sclerosis, beginning at a precursor very early stage of disease, with a focus on timely early detection of organ involvement.

TL;DR: The BE COMPLETE trial as discussed by the authors compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α (TNFα) inhibitors.